Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $987K | $2.04M | $1.49M | $1.79M | $198K | — | — | — | — | — |
| Revenue growth | — | 106.9% | -27.3% | 20.4% | -88.9% | — | — | — | — | — |
| Operating income | -$39.8M | -$38.0M | -$22.5M | -$16.2M | -$24.9M | -$30.3M | -$77.3M | -$41.3M | -$20.6M | -$26.1M |
| Operating margin | -4035.9% | -1862.7% | -1518.4% | -905.8% | -12572.2% | — | — | — | — | — |
| Net income | -$55.2M | -$39.5M | -$18.4M | -$20.5M | -$27.5M | -$32.6M | -$67.6M | -$39.2M | -$20.3M | -$1.79M |
| Net margin | -5589.7% | -1933.9% | -1242.2% | -1148.4% | -13876.3% | — | — | — | — | — |
| EPS (diluted) | -$7.98 | -$94.84 | -$24.14 | -$7.74 | -$2.51 | -$2.08 | -$2.73 | — | — | — |
| Fiscal year | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33.5M | -$33.6M | -$21.0M | -$15.8M | -$24.7M | -$25.3M | -$23.7M | -$19.5M | -$13.4M | -$15.4M |
| Capital expenditures | $458K | $281K | $24.0K | — | $191K | $291K | $279K | $13.0K | $15.0K | $12.0K |
| Free cash flow | -$34.0M | -$33.9M | -$21.1M | — | -$24.9M | -$25.6M | -$23.9M | -$19.5M | -$13.5M | -$15.4M |
| Dividends paid | — | — | — | — | — | — | — | — | $0.00 | $657K |
| Fiscal year | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $38.7M | $5.59M | $1.81M | $11.2M | $22.6M | $16.9M | $22.3M | $6.17M | $4.32M | $1.78M |
| Total assets | $44.4M | $9.70M | $3.35M | $119M | $119M | $113M | $74.8M | $38.0M | $32.4M | $27.9M |
| Total liabilities | $36.1M | $38.5M | $27.3M | $51.3M | $44.0M | $43.3M | $32.9M | $27.9M | $29.0M | $14.7M |
| Long-term debt | $25.0M | $25.0M | — | — | — | — | — | — | — | — |
| Shareholders' equity | $8.27M | -$28.8M | -$23.9M | $68.1M | $74.9M | $69.6M | $41.9M | $10.0M | $3.39M | $10.00M |
| Retained earnings | -$579M | -$619M | -$637M | -$658M | -$685M | -$718M | -$785M | -$825M | -$845M | -$847M |
| Shares (wtd avg diluted) | 6.97M | 8.33M | 1.03M | 32.1M | 13.7M | 16.9M | 495K | 630K | 4.30M | 52.6M |
Every figure is extracted from WINDTREE THERAPEUTICS INC /DE/’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.